A PharmAsia News update on Turkish biomedical regulatory policies, including a penicillin shortage and an update on a draft patent law.
ISTANBUL – A penicillin shortage continues in Turkey despite efforts to procure supplies for hospitals. Elsewhere, penalties for patent violations outlined in the new draft are the subject of hot discussions among producers of original drugs and generics.
Deva, a major Turkish pharmaceutical company called on the government to “improve” drug prices and update the euro exchange rate...
Create an account to read this article
Already a subscriber?
The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.
Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.
Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”
Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.
Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.
